Back to top

Delphi Technologies Inks Technology Partnership with TomTom

Read MoreHide Full Article

Delphi Technologies PLC (DLPH - Free Report) recently entered into a technology partnership with TomTom —a Netherlands-based provider of navigation, traffic and mapping products.

The two companies are collaborating on electronic and software applications, aimed at optimizing vehicle fuel efficiency with the help of real-time mapping data.

Shares of Delphi Technologies have declined 73.7% in the past year compared with 12.5% fall of the industry it belongs to.

 

The Partnership in Detail

Under the partnership, Delphi Technologies’ Intelligent Driving controls will be utilizing TomTom’s real-time mapping data to forecast changing driving conditions, such as route infrastructure and topography, traffic congestion and weather.  This is expected to improve vehicle fuel efficiency, reduce emissions and lower commutation time.

Mary Gustanski, chief technology officer, Delphi Technologies, stated, "Our collaboration with TomTom will help us to find new opportunities to integrate more information about a driver's route, in order to enhance our proprietary Intelligent Driving controls and allow vehicles to drive better, cleaner and further." 

Delphi Technologies' latest portfolio of automated and connected solutions is expected to make vehicles smarter, thus enhancing safety and improving ride experience.

Zacks Rank & Stocks to Consider

Delphi Technologies currently carries a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

A few better-ranked stocks in the broader Zacks Business Services sector are Republic Services (RSG - Free Report) , Waste Connections (WCN - Free Report) and Navigant Consulting (NCI - Free Report) , each carrying a Zacks Rank #2 (Buy). Long-term expected EPS (three to five years) growth rate for Republic Services, Waste Connections and Navigant is pegged at 10.7%, 11.7% and 13.5%, respectively.

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>



More from Zacks Analyst Blog

You May Like

Published in